Pluri secures global IP position with CNIPA for immune cell expansion

Pluri (PLUR) announces that the China National Intellectual Property Administration, CNIPA, has granted Pluri Biotech, a wholly owned subsidiary of Pluri, a patent covering its proprietary 3D immune cell expansion and activation technology. The patent, titled “System and Methods for Immune Cells Expansion and Activation in Large Scale,” expands Pluri’s global intellectual property portfolio, including granted patents in the United States and additional granted patents in Japan, Korea, Australia and Israel. The expanded portfolio supports the Company’s strategy to pursue global collaboration and licensing agreements for immune cell therapy products built on Pluri’s automated, large-scale manufacturing platform.